24/7 BIOPHARMA - issue 1 / October 2024

VERANOVA

Veranova is a global leader in process development and manufacturing of APIs, with a focus on specialty and complex products. The headquarters of Veranova is in Wayne, Pennsylvania, and it has operations in North America and Europe. Strategic partnerships between pharmaceutical and biotech companies and CDMOs are becoming increasingly critical for developers to deliver timely, accessible and affordable medicines. This evolving relationship is transforming the pharmaceutical industry across several key areas, creating faster drug development for businesses and better outcomes for patients. Over the past decade, the industry has made remarkable progress in shortening drug development timelines. While speed is important, it must never compromise patient safety or regulatory compliance. CDMOs can streamline drug development timelines by employing advanced Accelerating fast-to-market strategies

process development and optimisation techniques. By adopting cutting-edge technologies, CDMOs can shorten the journey from lab to clinic, lower costs and speed time-to-market. A notable example is Veranova’s May, 2024, partnership with Phorum.AI, which leverages artificial intelligence (AI) to optimise pharmaceutical manufacturing. By combining Veranova’s extensive datasets with Phorum.AI’s computational chemistry engine, this collaboration aims to enhance process efficiency, reduce costs and boost environmental sustainability. The pharmaceutical pipeline is shifting toward more complex and potent molecules designed for targeted, patient-specific therapies. These include antibody-drug conjugates (ADCs), protein degraders, peptides and RNA-based therapies. While these innovations hold immense promise, they also present new processing challenges due to their potency and more complex molecular structures compared to traditional small molecules. Innovating in therapeutic modalities

18

TWENTYFOURSEVENBIOPHARMA Issue 1 / October 2024